Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478751 · ClinicalTrials.gov registry record
Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 22
- Enrollment target
NCT00478751: Completed study, sponsored by Henry Ford Health System.
NCT00478751 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478751 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
* Determine the impact and the threshold of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals. * The study basically wants to understand what types of light make us tan.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-01 |
What the finished NCT00478751 record still lists
NCT00478751 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00478751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478751 about?
NCT00478751 is a clinical study titled "Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin". * Determine the impact and the threshold of long wavelength UVA and visible light on immediate and delayed pigment production of melanocompetent individuals. * The study basically wants to understand what types of light make us tan.
What is the current status of trial NCT00478751?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2007-05. Estimated completion is 2009-01.
Who is sponsoring clinical trial NCT00478751?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia